Palo Alto, California, August 22, 2024 – I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial using iPS cell-derived natural killer (iNK) cells for ovarian cancer immunotherapy. iCamuno will lead the trial, which will test the safety and efficacy of NK cells made from I Peace’s cGMP-compliant iPS cells using iCamuno’s NK cell differentiation technology. [Read more…]
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102™ in Patients with Dystrophic Epidermolysis Bullosa (“DEB”)
AGLE-102 is a novel extracellular vesicle therapy being developed for the treatment of rare and immuno-dermatological disorders.
WOBURN, Mass., Aug. 14, 2024 — Aegle Therapeutics Corp., a clinical-stage biopharmaceutical company developing novel extracellular vesicle (“EV”) therapies to address immune and inflammatory-based dermatological disorders, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating AGLE-102™ for the treatment of the rare pediatric skin blistering disease DEB. [Read more…]
Nucleus Biologics Launches QuickStart Media™: A Suite of Optimized Media Formulations That Provide a Head Start on Your Therapy Optimization
SAN DIEGO, August 08, 2024 — Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media and buffers for the cell and gene therapy industry, proudly announces the launch of a novel platform to expedite the formulation and manufacture of custom media. This platform, called QuickStart Media™, is a groundbreaking addition to its comprehensive line of cell culture products and solutions and further demonstrates Nucleus Biologics’ expertise and dedication to the delivery of custom cell culture media, buffers, reagents, and services simpler and faster. [Read more…]
NMDP BioTherapies and the NMDP BioTherapies Cord Blood Bank Alliance Introduce Optimal Cord Blood Units for Manufacture of NK Cell Therapies And Other Cord Derived Cell Therapies
Leveraging the Power of the NMDP BioTherapies Cord Blood Bank Alliance, Readily Accessible Cord Blood Units That Meet the Criteria Established in Marin, et al in Nature Medicine for Production of CAR-NK Cells
MINNEAPOLIS, July 18, 2024 — NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, and the NMDP BioTherapies Cord Blood Bank Alliance (CBBA), a partnership between NMDP BioTherapies and nine public cord blood banks, are making available pre-identified cord blood units that are optimized for manufacture of cord-derived cell therapies, and in particular cord-derived NK cell therapies. The identification and supply of these units leverages the over 200,000 cord blood units in the inventory of the CBBA as well as NMDP BioTherapies’ cord unit search platform, through which individual cord blood units that meet specific requirements can be rapidly identified. [Read more…]
Astellas, Universal Cells, and Osaka University to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas’ Universal Donor Cell Technology.
TOKYO and OSAKA, Japan, July 22, 2024 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) and Graduate School of Medicine / Faculty of Medicine, Osaka University (President: Shojiro Nishio) announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of Astellas, “AIRM”), Universal Cells (a wholly owned subsidiary of Astellas) and Osaka University have entered into a research collaboration to develop innovative pluripotent stem cell*1-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease*2. [Read more…]
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 117
- Next Page »